PF-06281355
- Product Name
- PF-06281355
- CAS No.
- 1435467-38-1
- Chemical Name
- PF-06281355
- Synonyms
- PF-1355;PF-06281355;PF-1355 (PF06281355;PF-1355, 10 mM in DMSO;PF-06281355 (Free base);PF-06281355 >=98% (HPLC);PF06281355;PF1355;PF 1355;PF-06281355;PF 06281355;6-(2,5-Dimethoxyphenyl)-3,4-dihydro-4-oxo-2-thioxo-1(2H)-pyrimidineacetamide;1(2H)-Pyrimidineacetamide, 6-(2,5-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-thioxo-;2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide
- CBNumber
- CB23146431
- Molecular Formula
- C14H15N3O4S
- Formula Weight
- 321.35
- MOL File
- 1435467-38-1.mol
PF-06281355 Property
- Density
- 1.43±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:1): 0.5mg/mL; DMSO: 10mg/mL; Ethanol: 5mg/mL
- form
- A crystalline solid
- pka
- 6.93±0.40(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- 22222
- Product name
- PF-06281355
- Packaging
- 1mg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 22222
- Product name
- PF-06281355
- Packaging
- 5mg
- Price
- $100
- Updated
- 2024/03/01
- Product number
- 22222
- Product name
- PF-06281355
- Packaging
- 10mg
- Price
- $184
- Updated
- 2024/03/01
- Product number
- 6004
- Product name
- PF06281355
- Purity
- ≥98%(HPLC)
- Packaging
- 50
- Price
- $710
- Updated
- 2021/12/16
- Product number
- 6004
- Product name
- PF06281355
- Purity
- ≥98%(HPLC)
- Packaging
- 10
- Price
- $170
- Updated
- 2021/12/16
PF-06281355 Chemical Properties,Usage,Production
Uses
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
Biological Activity
PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) th at reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease.
in vivo
Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment[1].
storage
Store at RT
References
[1] Zheng W, et al. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J Pharmacol Exp Ther. 2015 May;353(2):288-98 DOI:10.1124/jpet.114.221788
PF-06281355 Preparation Products And Raw materials
Raw materials
Preparation Products
PF-06281355 Suppliers
- Tel
- 025-846993838003-8003 18013301590
- Fax
- 025-84699383-8003
- njduly@126.com
- Country
- China
- ProdList
- 3249
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 15076683720
- Fax
- 022-23754520
- klq@cw-bio.com
- Country
- China
- ProdList
- 8011
- Advantage
- 55
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- Fax
- -
- 13006575422@163.com
- Country
- China
- ProdList
- 6355
- Advantage
- 58
- Tel
- 010-50973130 18101056239
- 3193328036@qq.com
- Country
- China
- ProdList
- 29760
- Advantage
- 68
- Tel
- 571-89925085
- Fax
- 0086-571-89925065
- sales@amadischem.com
- Country
- China
- ProdList
- 131957
- Advantage
- 58
- Tel
- +1-800-259-7612
- Fax
- +1-800-259-7612
- info@musechem.com
- Country
- United States
- ProdList
- 4660
- Advantage
- 60
- Tel
- Fax
- -
- jnyaoyan@163.com
- Country
- China
- ProdList
- 3069
- Advantage
- 58